SCHEMBL702371

SCHEMBL702371

COC(=O)c1cccc2c1c(C=O)cn2C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 5/20 0.52
KDR P35968 1/20 0.52
ALDH1A1 P00352 6/20 0.50
IMPDH2 P12268 1/20 0.50
POLB P06746 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 5/20 0.41
MEN1 O00255 3/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
PIM1 P11309 1/20 0.41
PIM3 Q86V86 1/20 0.41
BRD4 O60885 1/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.40
PKM P14618 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27988398 0.84 ALDH1A1 (0.50) NR4A2KDRALDH1A1IMPDH2POLB
SCHEMBL29953146 0.84 ALDH1A1 (0.50) NR4A2KDRALDH1A1IMPDH2POLB
SCHEMBL28454595 0.83 NR4A2 (0.50) NR4A2KDRALDH1A1POLBRAB9A
SCHEMBL20604857 0.81 NR4A2 (0.56) NR4A2KDRALDH1A1KMT2AMEN1
SCHEMBL15998939 0.81 NR4A2 (0.56) NR4A2KDRALDH1A1KMT2AMEN1
SCHEMBL27832099 0.81 NR4A2 (0.50) NR4A2KDRALDH1A1KMT2AMEN1
SCHEMBL703569 0.80 NR4A2 (0.49) NR4A2KDRALDH1A1KMT2AMEN1
SCHEMBL13806220 0.79 NR4A2 (0.55) NR4A2KDRALDH1A1KMT2AMEN1
SCHEMBL699995 0.78 APP (0.50) ALDH1A1POLBKMT2AMEN1GAA
SCHEMBL700424 0.78 ALDH1A1 (0.55) NR4A2ALDH1A1POLBRAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111606928-A Azacyclodiketone compound and preparation method thereof 维清生物科技(上海)有限公司 2020-09-01 CN disclosed
US-8710047-B2 5-HT3 receptor modulators, methods of making, and use thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2014-04-29 US disclosed
US-20130310366-A1 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2013-11-21 US disclosed
US-8501729-B2 5-HT3 receptor modulators, methods of making, and use thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2013-08-06 US disclosed
US-20120219641-A1 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2012-08-30 US disclosed
US-8124600-B2 5-HT3 receptor modulators, methods of making, and use thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2012-02-28 US disclosed
US-20090298809-A1 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2009-12-03 US disclosed
US-5272143-A 6-oxoazepinoindole compounds, and pharmaceutical compositions containing them KALI-CHEMIE PHARMA GMBH (DE) 1993-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310366-A1 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF HTR3A, HTR5A, HTR3B NR4A2 3653/4885KDR 2575/4885ALDH1A1 2992/4885
US-20090298809-A1 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF HTR3A, HTR5A, HTR3B NR4A2 3653/4885KDR 2575/4885ALDH1A1 2992/4885
US-20120219641-A1 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF HTR3A, HTR5A, HTR3B NR4A2 3653/4885KDR 2575/4885ALDH1A1 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.